Thought Leadership
Can the FDA Salvage Interchangeable Follow-On Biologics?
November 19, 2019
Ted Mathias and Stacie Ropka, PhD
BioProcess Online / Biosimilar Development

BioProcess Online and Biosimilar Development published "Can the FDA Salvage Interchangeable Follow-On Biologics?", an article co-written by Axinn partners Ted Mathias and Stacie Ropka.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.